{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T17:57:41Z","timestamp":1759773461565,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007682","name":"Medicinski Fakultet, Sveu\u010dili\u0161te u Zagrebu","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007682","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.mehy.2019.109313","type":"journal-article","created":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T18:01:45Z","timestamp":1563645705000},"page":"109313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Elevated plasma RANTES in fibrodysplasia ossificans progressiva \u2013 A novel therapeutic target?"],"prefix":"10.1016","volume":"131","author":[{"given":"Lovorka","family":"Grgurevi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru\u0111er","family":"Novak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Trkulja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lejla Ferhatovi\u0107","family":"Hamzi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stela","family":"Hrka\u010d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simeon","family":"Grazio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Santini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2019.109313_b0005","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.bone.2017.07.019","article-title":"Early clinical observations on the use of imatinib mesylate in FOP: a report of seven cases","volume":"109","author":"Kaplan","year":"2018","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.mehy.2019.109313_b0010","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ng1783","article-title":"A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva","volume":"38","author":"Shore","year":"2006","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.mehy.2019.109313_b0015","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/21678707.2017.1304211","article-title":"Hard targets for a second skeleton: therapeutic horizons for fibrodysplasia ossificans progressiva (FOP)","volume":"5","author":"Kaplan","year":"2017","journal-title":"Expert Opin Orphan Drugs"},{"key":"10.1016\/j.mehy.2019.109313_b0020","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.semcdb.2015.12.013","article-title":"Granting immunity to FOP and catching heterotopic ossification in the Act","volume":"49","author":"Kaplan","year":"2016","journal-title":"Semin Cell Dev Biol"},{"issue":"4","key":"10.1016\/j.mehy.2019.109313_b0025","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3390\/ijms19040989","article-title":"The horizon of a therapy for rare genetic diseases: a \u201cDruggable\u201d future for fibrodysplasia ossificans progressiva","volume":"19","author":"Cappato","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.mehy.2019.109313_b0030","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/jbmr.3304","article-title":"Depletion of mast cells and macrophages impairs heterotopic ossification in an Acvr 1(R206H) mouse model of fibrodysplasia ossificans progressiva","volume":"33","author":"Convente","year":"2018","journal-title":"J Bone Mineral Res"},{"key":"10.1016\/j.mehy.2019.109313_b0035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bone.2017.08.023","article-title":"Mast cell inhibition as a therapeutic approach in fibrodysplasia ossificans progressiva (FOP)","volume":"109","author":"Brennan","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.mehy.2019.109313_b0040","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jtemb.2016.10.001","article-title":"Trace element and cytokine concentrations in patients with Fibrodysplasia Ossificans Progressiva (FOP): a case control study","volume":"39","author":"Hildebrand","year":"2017","journal-title":"J Trace Elements Med Biol"},{"issue":"22","key":"10.1016\/j.mehy.2019.109313_b0045","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122958","article-title":"NF-\u03baB\/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification","volume":"3","author":"Barruet","year":"2018","journal-title":"JCI Insight"},{"issue":"12","key":"10.1016\/j.mehy.2019.109313_b0050","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1517\/14728222.2013.837886","article-title":"Targeting CCL5 in inflammation","volume":"17","author":"Marques","year":"2013","journal-title":"Expert Opin Therapeutic Targets"},{"issue":"5","key":"10.1016\/j.mehy.2019.109313_b0055","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.3390\/ijms19051477","article-title":"Inhibition of the CCL5\/CCR5 Axis against the progression of gastric cancer","volume":"19","author":"Aldinucci","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.mehy.2019.109313_b0060","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10456-012-9285-x","article-title":"RANTES\/CCL5-induced pro-angiogenic effects depend on CCR1, CCR5 and glycosaminoglycans","volume":"15","author":"Suffee","year":"2012","journal-title":"Angiogenesis"},{"issue":"11","key":"10.1016\/j.mehy.2019.109313_b0065","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1172\/JCI41732","article-title":"Antagonism of the chemokine CCL5 ameliorates experimental liver fibrosis in mice","volume":"120","author":"Berres","year":"2010","journal-title":"J Clin Investig"},{"issue":"2","key":"10.1016\/j.mehy.2019.109313_b0070","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1471-4906(00)01812-3","article-title":"RANTES: a versatile and controversial chemokine","volume":"22","author":"Appay","year":"2001","journal-title":"Trends Immunol"},{"issue":"2","key":"10.1016\/j.mehy.2019.109313_b0075","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/10428194.2011.605190","article-title":"The role of CD40\/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment","volume":"53","author":"Aldinucci","year":"2012","journal-title":"Leukemia Lymphoma"},{"issue":"3","key":"10.1016\/j.mehy.2019.109313_b0080","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5582\/bst.2014.01047","article-title":"CCL5\/RANTES is important for inducing osteogenesis of human mesenchymal stem cells and is regulated by dexamethasone","volume":"8","author":"Liu","year":"2014","journal-title":"Biosci Trends"},{"issue":"7","key":"10.1016\/j.mehy.2019.109313_b0085","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"issue":"1","key":"10.1016\/j.mehy.2019.109313_b0090","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.canlet.2013.10.006","article-title":"The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer","volume":"352","author":"Weitzenfeld","year":"2014","journal-title":"Cancer Lett"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987719306899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987719306899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:17:09Z","timestamp":1759691829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987719306899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":18,"alternative-id":["S0306987719306899"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2019.109313","relation":{},"ISSN":["0306-9877"],"issn-type":[{"type":"print","value":"0306-9877"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated plasma RANTES in fibrodysplasia ossificans progressiva \u2013 A novel therapeutic target?","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2019.109313","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109313"}}